ACHE and memory impairment: Importantly, MT‐01 was shown to ameliorate scopolamine‐induced memory impairment in behavioral tests, increase SOD activity, and decrease AChE activity in mice, compared to scopolamine‐treated mice with no MT‐01 administration.